{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-038077","form_type":"8-K","ticker":"TMDX","cik":"0001756262","company_name":"TransMedics Group, Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.124452+00:00","generated_at":"2026-06-12T08:56:17.621402+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"TransMedics Q2 revenue $52.5M, up 156% YoY; raises FY 2023 guidance to $180M-$190M","bullets":["Net revenue $52.5M in Q2 2023, up 156% from $20.5M YoY; net loss narrowed to $1.0M from $11.5M.","Full-year 2023 revenue guidance raised to $180M-$190M (93%-103% growth) from prior $160M-$170M.","U.S. National OCS Program drove ~93% of OCS cases; cash $582.2M after $393M convertible notes offering.","Gross margin steady at 70%; operating expenses $37.6M vs $24.1M; signed deal to acquire Summit Aviation."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-038077","json":"https://secwatch.observer/filing/0000950170-23-038077.json","markdown":"https://secwatch.observer/filing/0000950170-23-038077.md","text":"https://secwatch.observer/filing/0000950170-23-038077.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1756262/000095017023038077/0000950170-23-038077-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1756262/000095017023038077/tmdx-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T08:56:17.621402+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f332f589ef1d40807573c41011d6cdbb7b286890","claim":"TransMedics Group, Inc. reported full year 2023 results: revenue $180 million to $190 million. Guidance raised.","evidence_excerpt":"TransMedics is updating its full year 2023 revenue guidance to be in the range of $180 million to $190 million, which represents 93% to 103% growth compared to the company’s prior year revenue. TransMedics’ prior 2023 revenue guidance was $160 million to $170 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1756262/000095017023038077/0000950170-23-038077-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"$180 million to $190 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"f4edd972feb2489300cadd7d9c9e39796fd57b15","claim":"TransMedics Group, Inc. reported quarter ended June 30, 2023 results: net income Net loss for the second quarter of 2023 was $1.0 million, compared to $11.5 million in the second quarter of 2022..","evidence_excerpt":"Net revenue of $52.5 million in the second quarter of 2023, a 156% increase compared to the second quarter of 2022 .","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1756262/000095017023038077/0000950170-23-038077-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss for the second quarter of 2023 was $1.0 million, compared to $11.5 million in the second quarter of 2022."},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"f4edd972feb2489300cadd7d9c9e39796fd57b15","claim":"TransMedics Group, Inc. reported quarter ended June 30, 2023 results: net income Net loss for the second quarter of 2023 was $1.0 million, compared to $11.5 million in the second quarter of 2022..","evidence_excerpt":"Net loss for the second quarter of 2023 was $1.0 million, compared to $11.5 million in the second quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1756262/000095017023038077/0000950170-23-038077-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss for the second quarter of 2023 was $1.0 million, compared to $11.5 million in the second quarter of 2022."},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}